Recent Finacing
Recent Raise
IDRx is a clinical-stage biopharmaceutical developing precision combination therapies for KIT-mutant gastrointestinal stromal tumor, advancing oral KIT inhibitor IDRX-42 in Phase 1/1b and preclinical IDRX-73.
Focus Areas
Recent Investors
Total Raised
Funding rounds
Investors
